Bio Blast Pharma Ltd. (NASDAQ:ORPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $2.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research’s price target indicates a potential upside of 16.96% from the company’s previous close.
According to Zacks, “Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy’s disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel. “
ORPN has been the topic of several other research reports. Roth Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Bio Blast Pharma in a research note on Friday, August 26th. Rodman & Renshaw reiterated a “buy” rating on shares of Bio Blast Pharma in a research note on Monday, July 11th. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $19.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/bio-blast-pharma-ltd-orpn-upgraded-at-zacks-investment-research.html
Shares of Bio Blast Pharma (NASDAQ:ORPN) traded down 2.29% on Tuesday, reaching $1.71. 67,879 shares of the company’s stock were exchanged. Bio Blast Pharma has a one year low of $1.50 and a one year high of $7.95. The company’s 50 day moving average is $1.70 and its 200-day moving average is $2.04. The stock’s market cap is $28.03 million.
Bio Blast Pharma (NASDAQ:ORPN) last posted its earnings results on Thursday, August 25th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. During the same period in the previous year, the business posted ($0.26) earnings per share. On average, analysts anticipate that Bio Blast Pharma will post ($1.03) EPS for the current year.
An institutional investor recently bought a new position in Bio Blast Pharma stock. Sabby Management LLC bought a new stake in Bio Blast Pharma Ltd. (NASDAQ:ORPN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,133,937 shares of the biopharmaceutical company’s stock, valued at approximately $2,824,000. Sabby Management LLC owned 7.97% of Bio Blast Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 7.82% of the company’s stock.
About Bio Blast Pharma
Bio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Get a free copy of the Zacks research report on Bio Blast Pharma (ORPN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio Blast Pharma Ltd. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio Blast Pharma Ltd. and related companies with MarketBeat.com’s FREE daily email newsletter.